



(51) International Patent Classification:

A61K 47/68 (2017.01) *A61P 35/00* (2006.01)*A61K 38/05* (2006.01) *C07K 16/30* (2006.01)

(21) International Application Number:

PCT/IB2023/000193

(22) International Filing Date:

05 April 2023 (05.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2022-0043049 06 April 2022 (06.04.2022) KR

(71) Applicant: **LEGOCHEM BIOSCIENCES, INC.**
[KR/KR]; 10, Gukjegwahak 10-ro, Yuseong-gu, 34002 (KR).(72) Inventors: **PARK, Chang, Sil**; 10, Gukjegwahak 10-ro, Yuseong-gu, 34002 (KR). **SONG, Ho, Young**; 10, Gukjegwahak 10-ro, Yuseong-gu, 34002 (KR). **KIM, Hye, Jung**; 10, Gukjegwahak 10-ro, Yuseong-gu, 34002 (KR). **CHUNG, Chul-woong**; 10, Gukjegwahak 10-ro, Yuseong-gu, 34002 (KR).(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN TROP2 AND USE THEREOF

FIG. 1



(57) Abstract: The present disclosure relates to an antibody-drug conjugate (ADC) targeting human TROP2 (tumor-associated calcium signal transducer 2, TACSTD2)) and use thereof, and more particularly, to: an ADC including an antibody or antigen-binding fragment thereof that binds to human TROP2; and use of ADCs for producing a drug for the treatment and/or treatment of diseases, more particularly, hyperproliferative and/or angiogenic diseases, such as cancer diseases.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*